- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04968548
Bestemmelse og validering av en multianalyttanalyse for lungekreftscreening
Bestemmelse og validering av Lung EpiCheck®: En multianalytanalyse for lungekreftprediksjon. En case-control studie
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Studieoversikt
Detaljert beskrivelse
This is a prospective, case-control, multi-center, observational nonsignificant risk study. The study aims to collect blood and clinical data from subjects undergoing Low Dose CT (LDCT) for lung cancer screening and subjects with confirmed lung cancer.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- University of Calgary
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital/The University of British Columbia
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H4A3J1
- McGill University Health Centre
-
-
-
-
California
-
Encinitas, California, Forente stater, 92024
- Scripps Memorial Hospital
-
-
Colorado
-
Lakewood, Colorado, Forente stater, 80228
- Centura Health
-
-
Connecticut
-
West Haven, Connecticut, Forente stater, 06516
- VA Connecticut Healthcare System
-
-
Florida
-
Orlando, Florida, Forente stater, 32806
- Orlando Health, Inc.
-
Sarasota, Florida, Forente stater, 34239
- Sarasota Memorial Hospital
-
-
Kentucky
-
Edgewood, Kentucky, Forente stater, 41017
- St. Elizabeth Edgewood Hospital
-
Louisville, Kentucky, Forente stater, 40202
- Norton Cancer Institute
-
Owensboro, Kentucky, Forente stater, 42303
- Owensboro Health
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins Medical Center
-
-
Massachusetts
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota Health
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65201
- Harry S. Truman Memorial Veterans' Hospital
-
St Louis, Missouri, Forente stater, 63110
- Washington University in St. Louis
-
-
New York
-
New Hyde Park, New York, Forente stater, 11040
- Northwell Health
-
Rochester, New York, Forente stater, 14627
- University of Rochester
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- The University of North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Duke University
-
Durham, North Carolina, Forente stater, 27710
- Durham VA Health Care System
-
Salisbury, North Carolina, Forente stater, 28144
- W.G. (Bill) Hefner VA Medical Center
-
Winston-Salem, North Carolina, Forente stater, 27103
- Novant Health Cancer Research
-
-
Ohio
-
Akron, Ohio, Forente stater, 44304
- Summa Health
-
Cleveland, Ohio, Forente stater, 44106
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29401
- Ralph H. Johnson VA Medical Center
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina (MUSC)
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38120
- Baptist Cancer Center
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Michael E. DeBakey VA Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The Case Series will include subjects 50-80 years old, current or past smokers with at least 20 pack-years, with either (a) a high suspicion for lung cancer, who are planning to undergo surgery to establish a definitive diagnosis; or (b) confirmed lung cancer diagnosis, however did not yet undergo any treatment for this cancerous lesion.
The Screening Series will include subjects 50-80 years old, current or past smokers, with at least 20 pack-years, undergoing LDCT for lung cancer screening.
All subjects should be without other cancer in the past 5 years except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
Beskrivelse
Inclusion Criteria - Cases:
- Current or past smokers, with at least 20 pack-years
- Subjects with either A high suspicion for lung cancer, with planned surgery to establish a definitive diagnosis within 60 days after date of blood collection OR treatment naive lung cancer patients
Exclusion Criteria - Cases:
- Known diagnosis or treatment of any previous cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
- Current lung cancer is known to be stage III or IV by pathology.
Inclusion Criteria - Screening:
- Current or past smokers, with at least 20 pack-years, undergoing LDCT for lung cancer screening
Exclusion Criteria - Screening:
- Known diagnosis or treatment of any cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
- Subjects whose purpose of performing LDCT is for surveillance of a lung nodule
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Cases Series
Subjects with confirmed lung cancer diagnosis |
Peripheral blood will be collected via routine venipuncture procedure |
|
Screening Series
Subjects undergoing LDCT for lung cancer screening |
Peripheral blood will be collected via routine venipuncture procedure |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Collection of blood samples
Tidsramme: 24 Months
|
Collect blood to support the development and validation of a multi analyte test for lung cancer screening |
24 Months
|
|
Clinical data collection
Tidsramme: 24 Months
|
Collect clinical data to support the development and validation of a multi analyte test for lung cancer screening |
24 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance
Tidsramme: 36 Months
|
Performance of the assay in terms of (1) Sensitivity (2) Specificity (3) NPV (negative predictive value) and (4) PPV (positive predictive value) |
36 Months
|
|
Sensitivity
Tidsramme: 36 Months
|
Performance of the assay in terms of Sensitivity |
36 Months
|
|
Specificity
Tidsramme: 36 Months
|
Performance of the assay in terms of Specificity |
36 Months
|
|
Negative Predictive Value
Tidsramme: 36 Months
|
Performance of the assay in terms of NPV (negative predictive value) |
36 Months
|
|
Positive Predictive Value
Tidsramme: 36 Months
|
Performance of the assay in terms of PPV (positive predictive value) |
36 Months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Radha Duttagupta, PhD, Nucleix Ltd.
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Undersøkelsesteknikker
- Prøvehåndtering
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Punkteringer
- Kirurgiske prosedyrer, operativ
- Blodprøveinnsamling
Andre studie-ID-numre
- Lung-RND-003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .